Related Experiment Video
Updated: Jul 6, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Neoadjuvant chemotherapy in stage III NSCLC
Jeffrey Allen1, Mohammad Jahanzeb
1University of Tennessee Cancer Institute, Memphis, Tennessee, USA.
Summary
Neoadjuvant chemotherapy offers potential benefits for non-small cell lung cancer (NSCLC) treatment, especially for stage III disease. This review examines data on neoadjuvant chemotherapy for resectable, regionally advanced NSCLC.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the U.S.
- Standard treatment involves surgery followed by adjuvant chemotherapy for stages II and III.
- Neoadjuvant chemotherapy is an alternative treatment strategy.
Purpose of the Study:
- To review existing data on neoadjuvant chemotherapy for NSCLC.
- To focus on its application in regionally advanced (stage III) NSCLC amenable to resection.
Main Methods:
- Review of randomized and nonrandomized clinical trials.
- Analysis of data concerning neoadjuvant chemotherapy efficacy and safety.
- Focus on stage III NSCLC patients eligible for surgery.
Main Results:
- Neoadjuvant chemotherapy may offer advantages over adjuvant chemotherapy.
- Evidence from clinical trials is being evaluated.
- The review synthesizes current data on this treatment approach.
Conclusions:
- Neoadjuvant chemotherapy is a viable option for select NSCLC patients.
- Further research and clinical trials are ongoing.
- This approach warrants consideration for resectable stage III NSCLC.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...